article thumbnail

UTMB and HDT Bio receive US funding for vaccine development

Pharmaceutical Technology

in a project agreement from the US government for developing self-amplifying RNA (saRNA) vaccine technology against advanced and emergent viral threats. Development of vaccines to Phase I trials under the five-year $59m prototype project comprises additional $28.4m in milestone payments.

Vaccine 147
article thumbnail

Cancer patients overlooked in COVID-19 vaccine rollout

Scienmag

states failed to prioritize cancer patients for COVID-19 vaccinations, despite recommendations from the Centers for Disease Control and Prevention (CDC), according to a study being presented today at the annual meeting of the Radiological Society of North America (RSNA). CHICAGO – Almost two-thirds of U.S.

Vaccine 80
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Axillary lymphadenopathy after COVID-19 vaccine booster—time to resolution on ultrasound follow-up

Medical Xpress

According to an accepted manuscript published in ARRS' American Journal of Roentgenology (AJR), axillary lymphadenopathy after a COVID-19 vaccine booster dose has a mean time to resolution of 102 days, shorter than the time to resolution after the initial series.

Vaccine 98
article thumbnail

UK sets aside £248m to “digitise” NHS diagnostics

pharmaphorum

It will also be used to provide a tool to help GPs and other clinicians choose the most suitable scan for their patient based on symptoms and medical history, so as to reduce “inappropriate” requests made to radiology departments, it added.

Radiology 111
article thumbnail

Sanofi and GSK COVID-19 vaccine candidate demonstrates strong immune responses across all adult age groups in Phase 2 trial

The Pharma Data

Adjuvanted recombinant COVID-19 vaccine candidate triggered strong neutralizing antibody responses in all adult age groups. Overall, the vaccine candidate elicited strong neutralizing antibody levels that were comparable to those generated by natural infection, with higher levels observed in younger adults (18 to 59 years old).

article thumbnail

Sophia Genetics launches AI tool to find COVID-19 ‘unknowns’

pharmaphorum

This could potentially have a major impact on the efficacy and safety of candidate vaccines and antiviral therapies. The new tool can be used by labs to support their own COVID-19 research projects on their local patient base, and in turn could be used by pharma companies that are developing candidates vaccines and antiviral therapies.

Genetics 136
article thumbnail

AZD1222 US Phase III primary analysis confirms safety and efficacy

The Pharma Data

76% vaccine efficacy against symptomatic COVID-19. Positive high-level results from the primary analysis of the Phase III trial of AZD1222 in the US have confirmed vaccine efficacy consistent with the pre-specified interim analysis announced on Monday 22 March 2021. 100% efficacy against severe or critical disease and hospitalisation.

Vaccine 52